Cargando…

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells

BACKGROUND: Pulmonary arterial hypertension is a proliferative vascular disease, characterized by aberrant regulation of smooth muscle cell proliferation and apoptosis in distal pulmonary arteries. Prostacyclin (PGI(2)) analogues have anti-proliferative effects on distal human pulmonary artery smoot...

Descripción completa

Detalles Bibliográficos
Autores principales: Growcott, Ellena J, Spink, Karen G, Ren, Xiaohui, Afzal, Saliha, Banner, Kathy H, Wharton, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1386664/
https://www.ncbi.nlm.nih.gov/pubmed/16423283
http://dx.doi.org/10.1186/1465-9921-7-9
_version_ 1782126870574137344
author Growcott, Ellena J
Spink, Karen G
Ren, Xiaohui
Afzal, Saliha
Banner, Kathy H
Wharton, John
author_facet Growcott, Ellena J
Spink, Karen G
Ren, Xiaohui
Afzal, Saliha
Banner, Kathy H
Wharton, John
author_sort Growcott, Ellena J
collection PubMed
description BACKGROUND: Pulmonary arterial hypertension is a proliferative vascular disease, characterized by aberrant regulation of smooth muscle cell proliferation and apoptosis in distal pulmonary arteries. Prostacyclin (PGI(2)) analogues have anti-proliferative effects on distal human pulmonary artery smooth muscle cells (PASMCs), which are dependent on intracellular cAMP stimulation. We therefore sought to investigate the involvement of the main cAMP-specific enzymes, phosphodiesterase type 4 (PDE4), responsible for cAMP hydrolysis. METHODS: Distal human PASMCs were derived from pulmonary arteries by explant culture (n = 14, passage 3–12). Responses to platelet-derived growth factor-BB (5–10 ng/ml), serum, PGI(2 )analogues (cicaprost, iloprost) and PDE4 inhibitors (roflumilast, rolipram, cilomilast) were determined by measuring cAMP phosphodiesterase activity, intracellular cAMP levels, DNA synthesis, apoptosis (as measured by DNA fragmentation and nuclear condensation) and matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) production. RESULTS: Expression of all four PDE4A-D genes was detected in PASMC isolates. PDE4 contributed to the main proportion (35.9 ± 2.3%, n = 5) of cAMP-specific hydrolytic activity demonstrated in PASMCs, compared to PDE3 (21.5 ± 2.5%), PDE2 (15.8 ± 3.4%) or PDE1 activity (14.5 ± 4.2%). Intracellular cAMP levels were increased by PGI(2 )analogues and further elevated in cells co-treated with roflumilast, rolipram and cilomilast. DNA synthesis was attenuated by 1 μM roflumilast (49 ± 6% inhibition), rolipram (37 ± 6%) and cilomilast (30 ± 4%) and, in the presence of 5 nM cicaprost, these compounds exhibited EC(50 )values of 4.4 (2.6–6.1) nM (Mean and 95% confidence interval), 59 (36–83) nM and 97 (66–130) nM respectively. Roflumilast attenuated cell proliferation and gelatinase (MMP-2 and MMP-9) production and promoted the anti-proliferative effects of PGI(2 )analogues. The cAMP activators iloprost and forskolin also induced apoptosis, whereas roflumilast had no significant effect. CONCLUSION: PDE4 enzymes are expressed in distal human PASMCs and the effects of cAMP-stimulating agents on DNA synthesis, proliferation and MMP production is dependent, at least in part, on PDE4 activity. PDE4 inhibition may provide greater control of cAMP-mediated anti-proliferative effects in human PASMCs and therefore could prove useful as an additional therapy for pulmonary arterial hypertension.
format Text
id pubmed-1386664
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13866642006-03-02 Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells Growcott, Ellena J Spink, Karen G Ren, Xiaohui Afzal, Saliha Banner, Kathy H Wharton, John Respir Res Research BACKGROUND: Pulmonary arterial hypertension is a proliferative vascular disease, characterized by aberrant regulation of smooth muscle cell proliferation and apoptosis in distal pulmonary arteries. Prostacyclin (PGI(2)) analogues have anti-proliferative effects on distal human pulmonary artery smooth muscle cells (PASMCs), which are dependent on intracellular cAMP stimulation. We therefore sought to investigate the involvement of the main cAMP-specific enzymes, phosphodiesterase type 4 (PDE4), responsible for cAMP hydrolysis. METHODS: Distal human PASMCs were derived from pulmonary arteries by explant culture (n = 14, passage 3–12). Responses to platelet-derived growth factor-BB (5–10 ng/ml), serum, PGI(2 )analogues (cicaprost, iloprost) and PDE4 inhibitors (roflumilast, rolipram, cilomilast) were determined by measuring cAMP phosphodiesterase activity, intracellular cAMP levels, DNA synthesis, apoptosis (as measured by DNA fragmentation and nuclear condensation) and matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) production. RESULTS: Expression of all four PDE4A-D genes was detected in PASMC isolates. PDE4 contributed to the main proportion (35.9 ± 2.3%, n = 5) of cAMP-specific hydrolytic activity demonstrated in PASMCs, compared to PDE3 (21.5 ± 2.5%), PDE2 (15.8 ± 3.4%) or PDE1 activity (14.5 ± 4.2%). Intracellular cAMP levels were increased by PGI(2 )analogues and further elevated in cells co-treated with roflumilast, rolipram and cilomilast. DNA synthesis was attenuated by 1 μM roflumilast (49 ± 6% inhibition), rolipram (37 ± 6%) and cilomilast (30 ± 4%) and, in the presence of 5 nM cicaprost, these compounds exhibited EC(50 )values of 4.4 (2.6–6.1) nM (Mean and 95% confidence interval), 59 (36–83) nM and 97 (66–130) nM respectively. Roflumilast attenuated cell proliferation and gelatinase (MMP-2 and MMP-9) production and promoted the anti-proliferative effects of PGI(2 )analogues. The cAMP activators iloprost and forskolin also induced apoptosis, whereas roflumilast had no significant effect. CONCLUSION: PDE4 enzymes are expressed in distal human PASMCs and the effects of cAMP-stimulating agents on DNA synthesis, proliferation and MMP production is dependent, at least in part, on PDE4 activity. PDE4 inhibition may provide greater control of cAMP-mediated anti-proliferative effects in human PASMCs and therefore could prove useful as an additional therapy for pulmonary arterial hypertension. BioMed Central 2006 2006-01-19 /pmc/articles/PMC1386664/ /pubmed/16423283 http://dx.doi.org/10.1186/1465-9921-7-9 Text en Copyright © 2006 Growcott et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Growcott, Ellena J
Spink, Karen G
Ren, Xiaohui
Afzal, Saliha
Banner, Kathy H
Wharton, John
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
title Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
title_full Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
title_fullStr Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
title_full_unstemmed Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
title_short Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
title_sort phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1386664/
https://www.ncbi.nlm.nih.gov/pubmed/16423283
http://dx.doi.org/10.1186/1465-9921-7-9
work_keys_str_mv AT growcottellenaj phosphodiesterasetype4expressionandantiproliferativeeffectsinhumanpulmonaryarterysmoothmusclecells
AT spinkkareng phosphodiesterasetype4expressionandantiproliferativeeffectsinhumanpulmonaryarterysmoothmusclecells
AT renxiaohui phosphodiesterasetype4expressionandantiproliferativeeffectsinhumanpulmonaryarterysmoothmusclecells
AT afzalsaliha phosphodiesterasetype4expressionandantiproliferativeeffectsinhumanpulmonaryarterysmoothmusclecells
AT bannerkathyh phosphodiesterasetype4expressionandantiproliferativeeffectsinhumanpulmonaryarterysmoothmusclecells
AT whartonjohn phosphodiesterasetype4expressionandantiproliferativeeffectsinhumanpulmonaryarterysmoothmusclecells